Axsome治疗公司与心理健康美国（MHA）联合发声，强调心理健康月的重要性-动脉网

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Axsome Therapeutics 等信源发布 2025-05-01 20:12



可切换为仅中文







Download PDF

下载PDF

NEW YORK

纽约

，

May 01, 2025

2025年5月1日

(GLOBE NEWSWIRE) --

（环球新闻网）--

Axsome Therapeutics, Inc.

(NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with

(NASDAQ: AXSM)，一家引领中枢神经系统（CNS）疾病治疗新时代的生物制药公司，今天宣布将与

Mental Health America

美国心理健康协会

(MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May’s Mental Health Month.

（MHA）和更广泛的心理健康倡导社区在五月的心理健康月期间共同努力提高意识并促进行动。

打开

May 1

5月1日

, as part of Mental Health America’s “Light Up Green” initiative, Axsome’s

作为心理健康美国“点亮绿色”计划的一部分，Axsome公司的

New York City

纽约市

headquarters, the

总部，中心办公室

One World Trade Center

世界贸易中心一号楼

building, will be lit in green, the color for mental health awareness, and through the building’s Spireworks program.

大楼将被点亮为绿色，这是心理健康意识的颜色，并通过大楼的尖顶工程计划。

“Mental Health America’s 2024 data confirm what we already know to be true: We are in a mental health crisis that can affect anyone, anywhere,” said

“美国心理健康协会的2024年数据证实了我们已经知道的事实：我们正处于一场可能影响任何人、任何地方的心理健康危机之中，”

Schroeder Stribling

施罗德·斯特里布林

, president and CEO of

，总裁兼首席执行官

Mental Health America

美国心理健康协会

. “Mental health is health, and it affects us all. There are many social and environmental stressors impacting individuals and families across the country—whether you’re someone who lives in a remote rural community, a young person facing online bullying, or someone who is bearing the weight of family financial strain, one’s mental health is directly impacted.

“心理健康就是健康，它影响着我们所有人。全国范围内有许多社会和环境压力因素影响着个人和家庭——无论你是一个生活在偏远农村社区的人，一个面临网络欺凌的年轻人，还是一个承受家庭经济压力的人，心理健康都会直接受到影响。”

We hope that our Mental Health Month resources shine a light on these issues and support the needs of those who are seeking to understand and improve their mental health.”.

我们希望我们的心理健康月资源能够揭示这些问题，并支持那些寻求理解并改善他们心理健康的需要。

The impact of mental health conditions is significant in

心理健康状况的影响是显著的在

the United States

美国

, with nearly 1 in 4 adults in the

，近四分之一的成年人

U.S.

美国

living with a mental illness.

与精神疾病共存。

More than 1 in 8 people aged 12 or older in the

12岁或以上的人群中，超过八分之一的人员

U.S.

美国

felt depressed in the past two weeks, according to a recent study, highlighting the ubiquity and significant impact that depression has in the

根据最近的一项研究，过去两周感到抑郁，突显了抑郁症的普遍性和重大影响

U.S.

美国

In particular, nearly 90% of people living with depression report at least some difficulty with work, home or social activities due to their symptoms, contributing to the challenge of keeping up with day-to-day life.

特别是，近 90% 的抑郁症患者报告称，由于症状影响，他们在工作、家庭或社交活动中至少存在一些困难，这给跟上日常生活带来了挑战。

Axsome’s mission is to improve the lives of individuals living with serious CNS conditions that are difficult to treat or have limited treatment options by developing innovative evidence-based treatments that offer meaningful improvements to the standard of care. And, in the spirit of this year’s Mental Health Month theme of “Turning Advocacy into Action,” Axsome is highlighting the following resources for individuals and communities to take action for themselves or others:.

Axsome的使命是通过开发创新的、基于证据的治疗方法，为那些难以治疗或治疗选择有限的中枢神经系统疾病患者提供有意义的生活改善。并且，本着今年心理健康月主题“将倡导转化为行动”的精神，Axsome强调了以下资源，供个人和社区为自己或他人采取行动。

Mental Health America’s Mental Health Month Action Guide

美国心理健康协会的心理健康月行动指南

(

https://mhanational.org/mental-health-month/action-guide/

). MHA's work is driven by its commitment to promote mental health as a critical part of overall wellness, including prevention services for all; early identification and intervention for those at risk; and integrated care, services, and support for those who need them, with recovery as the goal. Resources to take action for your or others’ personal mental well-being provided by the MHA include its .

). MHA 的工作由其致力于将心理健康作为整体健康的重要组成部分来推动，包括为所有人提供预防服务；为有风险的人提供早期识别和干预；以及为需要的人提供综合护理、服务和支持，以康复为目标。MHA 提供的资源旨在为您的或他人的个人心理健康采取行动，包括其。

Online Screening Tools

在线筛查工具

，

Youth Leadership Programs

青年领导力项目

and the opportunity

和机会

to become a mental health advocate

成为一名心理健康倡导者

。

Anxiety and Depression Association

焦虑和抑郁协会

of America’s (ADAA)

美国（ADAA）

Mental Health Webinars

心理健康网络研讨会

(

（

https://adaa.org/resources-news/from-adaa-experts/webinars

) can address your questions about mental health conditions. ADAA’s mission focuses on improving quality of life for those with anxiety, depression, OCD, PTSD, and co-occurring disorders through education, practice, and research. ADAA’s resources also include

）可以解答您关于心理健康状况的问题。ADAA的使命是通过教育、实践和研究，改善焦虑症、抑郁症、强迫症、创伤后应激障碍以及共病患者的生活质量。ADAA的资源还包括

free online peer support groups

免费在线同伴支持小组

。

National Alliance on Mental Illness’ (NAMI) Mental Health Awareness Month Campaign

全国精神疾病联盟 (NAMI) 的心理健康意识月活动

(

https://www.nami.org/get-involved/awareness-events/mental-health-awareness-month/

). NAMI is the nation’s largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness. NAMI is also asking people to share their story as part of their “In Every Story, There’s Strength” campaign. You can learn more about the campaign and submit a short story to NAMI .

). NAMI是美国最大的基层心理健康组织，致力于为数百万受精神疾病影响的美国人建设更美好的生活。NAMI还要求人们分享他们的故事，作为其“在每个故事中，都有力量”活动的一部分。您可以了解更多关于该活动的信息，并向NAMI提交一个简短的故事。

here

这里

。

If you or someone you know is in crisis, the

如果您或您认识的人处于危机之中，

988 Suicide & Crisis Lifeline

988 自杀与危机生命热线

(

https://988lifeline.org/

) is a free confidential support service available 24 hours a day, 7 days a week across

）是一项免费的保密支持服务，每天24小时、每周7天全天候提供支持。

the United States

美国

. When people call, text, or chat 988, they will be connected to trained counselors that are part of the existing Lifeline network. These trained counselors will listen, understand how their problems are affecting them, provide support, and connect them to resources if necessary.

当人们拨打、发送短信或通过988进行聊天时，他们将被连接到现有生命线网络中受过训练的辅导员。这些受过训练的辅导员将会倾听他们的声音，理解他们的问题如何影响他们，提供支持，并在必要时将他们与资源联系起来。

About

关于

Axsome Therapeutics

is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes.

是一家引领中枢神经系统（CNS）疾病治疗新时代的生物制药公司。我们通过识别护理中的关键缺口，开发具有新颖作用机制的差异化产品，从而实现科学突破，为患者带来有意义的治疗进步。

Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in .

我们行业领先的神经科学产品组合包括FDA批准的治疗重度抑郁症、与嗜睡症和阻塞性睡眠呼吸暂停相关的过度日间嗜睡以及偏头痛的药物，并且我们还有多个处于后期开发阶段的项目，针对影响超过1.5亿人的各种严重的神经和精神疾病。

the United States

美国

. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at

。我们一起致力于解决大脑的一些最大问题，以便患者及其亲人能够茁壮成长。欲了解更多信息，请访问我们的网站

www.axsome.com

and follow us on

关注我们

领英

and

和

。

Forward Looking Statements

前瞻性声明

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

本新闻稿中讨论的某些事项属于“前瞻性陈述”。公司在某些情况下可能会使用“预测”、“相信”、“潜在”、“继续”、“估计”、“预期”、“计划”、“意图”、“可能”、“能够”、“也许”、“将”、“应该”等词语来表达未来事件或结果的不确定性，以识别这些前瞻性陈述。

In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s Sunosi.

特别是，公司关于趋势和潜在未来结果的声明是此类前瞻性陈述的示例。前瞻性陈述包含风险和不确定性，包括但不限于公司Sunosi的商业成功。

, Auvelity

，Auvelity

, and Symbravo

，以及Symbravo

products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain .

产品以及公司为solriamfetol和/或AXS-05获得任何额外适应症的努力的成功；公司维持和扩大支付方覆盖的能力；公司正在进行的临床试验及预计进行的临床试验的成功、时间安排和成本，针对公司当前候选产品的声明，包括关于试验启动时间、入组进度和完成情况（包括公司能否全额资助其已披露的临床试验，这假设公司目前预测的收入或支出没有重大变化）、无效性分析及中期结果的获取，这些结果不一定代表公司正在进行的临床试验的最终结果，和/或数据读出，以及支持公司任一当前候选产品提交新药申请（“NDA”）所需的研究所涉及的数量、类型或结果性质；公司为继续推进其候选产品而资助额外临床试验的能力；公司获得和维护的时间和能力。

U.S. Food and Drug Administration

美国食品药品监督管理局

(“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of Sunosi, Auvelity, and Symbravo and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control.

美国食品药品监督管理局（“FDA”）或其他监管机构对公司产品候选物的批准或其他相关行动，包括任何新药申请（NDA）提交时间的声明；公司成功捍卫其知识产权或以可接受的成本获得必要许可的能力（如果可以的话）；公司研发项目及合作的成功实施；公司许可协议的成功执行；市场对公司产品及其候选产品的接受程度（如获批准）；公司预期的资本需求，包括用于Sunosi、Auvelity和Symbravo商业化以及公司其他产品候选物商业发布的资本金额（如获批准），及其对公司预期现金跑道的潜在影响；公司将销售额转化为确认收入并保持有利的总销售额至净销售额比率的能力；由于国内政治气候、地缘政治冲突或全球性疫情引发或相关的意外情况或其他对正常业务运营的干扰，以及其他不受公司控制的因素，包括一般经济状况和监管发展。

The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances..

本文讨论的因素可能导致实际结果和发展与这些陈述中表达或暗示的内容存在重大差异。前瞻性陈述仅在本新闻稿发布之日作出，公司不承担公开更新此类前瞻性陈述以反映后续事件或情况的义务。

Investors:

投资者：

Mark Jacobson

马克·雅各布森

Chief Operating Officer

首席运营官

(212) 332-3243

mjacobson@axsome.com

Media:

媒体：

Darren Opland